---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-010785"
form_type: "8-K"
ticker: "ADCT"
cik: "0001771910"
company_name: "ADC Therapeutics SA"
filed_at: "2024-03-13T23:59:59+00:00"
generated_at: "2026-06-04T22:27:50.297580+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# ADC Therapeutics reports Q4'23 ZYNLONTA sales $16.6M, net loss $85M; cash runway into Q4'25

## Summary
- ZYNLONTA net sales $16.6M in Q4'23 (+17% QoQ, -16% YoY); FY'23 $69.1M (-8% YoY).
- Net loss $85M in Q4'23 ($1.03/share) vs $23.3M loss in Q4'22; FY'23 net loss $240.1M ($2.94/share).
- Cash $278.6M, expected runway into Q4'25; operating expenses decreased 21% YoY.
- LOTIS-5 may need additional patients beyond 350; enrollment still expected to complete in 2024.
- ADCT-601 pancreatic cancer screening initiated; LOTIS-7 dose escalation cleared at 150 µg/kg.

## SEC filing metadata
- accession: 0001628280-24-010785
- form_type: 8-K
- ticker: ADCT
- cik: 0001771910
- company_name: ADC Therapeutics SA
- filed_at: 2024-03-13T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1771910/000162828024010785/0001628280-24-010785-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1771910/000162828024010785/adc-20240313.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-010785
- JSON: https://secwatch.observer/filing/0001628280-24-010785.json
- Plain text: https://secwatch.observer/filing/0001628280-24-010785.txt

## Key facts
- Earnings Releases
  ADC Therapeutics SA reported financial results for fourth quarter and full year ended December 31, 2023.
  - Period: fourth quarter and full year ended December 31, 2023
  - Result: reported results
  source text: On March 13, 2024, ADC Therapeutics SA (the “Company”) issued a press release and made available a corporate presentation announcing the Company’s financial results for the full year and fourth quarter ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1771910/000162828024010785/0001628280-24-010785-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.